MapLight Therapeutics Reports Q1 Net Loss of $60.7M, EPS Improves to $(1.34) Amid Key Phase 2 Trial Progress
MPLT has more than doubled off its 52-week low of $12.24.
Summary
MapLight Therapeutics reported a first-quarter 2026 net loss of $(60.7M), widening from $(22.3M) in the prior year, primarily due to increased R&D spending as the company advances its clinical pipeline. Despite the increased net loss, diluted EPS significantly improved to $(1.34) from $(29.33) in Q1 2025, reflecting changes in the share base. The company confirmed a strong liquidity position of $395.2M in cash and investments, which management states supports operations through 2027. Crucially, MapLight announced upcoming topline results for two Phase 2 programs (ZEPHYR for schizophrenia and IRIS for autism spectrum disorder) in mid-August 2026, representing significant near-term catalysts. The VISTA Phase 2 program for Alzheimer's psychosis is also ongoing, and ML-007C-MA received FDA Fast Track designation. Traders will focus on the upcoming Phase 2 data readouts as key value inflection points.
At the time of this announcement, MPLT was trading at $29.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $12.24 to $33.28. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.